Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Breast 3Other hematologic neoplasm 2Gastrointestinal 2CNS 2Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 1Nausea 1Multiple Myeloma 1Lymphoma 1

Interventions

Rituximab 531Cyclophosphamide 426Vincristine 219Doxorubicin 193fludarabine phosphate 177Prednisone 167Etoposide 167fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Brentuximab Vedotin 55Antilymphocyte Serum 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Palonosetron × Lymphoid × Clear all
NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

University of Kansas Medical Center

Phase 2 Completed
20 enrolled 8 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡